Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active-Controlled Trial of the Safety and Tolerability of MP29-02 in Chronic Allergic or Nonallergic Rhinitis
2011-001368-23Phase 3
- Sponsor
- MedPointe Healthcare
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine + fluticasone in perennial rhinitis and non-allergic rhinitis (NAR) (2 arms), sponsored by MedPointe Healthcare. Primary endpoint: Frequency of patient-reported adverse events.
02
Drugs
azelastine + fluticasone
03
Conditions
perennial rhinitisnon-allergic rhinitis (NAR)
Beyond the preview
Go deeper on 2011-001368-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001368-23.